Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications
A pharmacological and clinical profile of Naxitamab for the treatment of high-risk neuroblastoma.
Journal: Expert review of clinical pharmacology
Published: October 20, 2025
Ganglioside Profiling Uncovers Distinct Patterns in High-Risk Neuroblastoma.
Journal: International journal of molecular sciences
Published: August 01, 2025
Affinity Affects the Functional Potency of Anti-GD2 Antibodies by Target-Mediated Drug Disposition.
Journal: Cancers
Published: June 04, 2025
Pulmonary Toxicity Associated With Concurrent Lorlatinib and Anti-GD2 Monoclonal Antibody Therapy in Patients With Neuroblastoma.
Journal: Pediatric blood & cancer
Published: March 13, 2025
Rapid COJEC without myeloablative therapy for high-risk neuroblastoma.
Journal: International journal of cancer
Published: February 18, 2025
A novel therapeutic strategy for osteosarcoma using anti-GD2 ADC and EZH2 inhibitor.
Journal: Biomarker research
Published: January 20, 2025
Adverse Reaction Reporting for Naxitamab in Chinese Expanded Access Treatment for Relapsed/Refractory High-Risk Neuroblastoma at the Children's Hospital of Fudan University.
Journal: Drugs - real world outcomes
Published: November 12, 2024
High-risk neuroblastoma in Mexico: from multimodal treatment to immunotherapy. Regarding the first case treated with naxitamab.
Journal: Frontiers in oncology
Published: October 30, 2024
A Phase II Trial of Naxitamab plus Stepped-up Dosing of GM-CSF for Patients with High-Risk Neuroblastoma in First Complete Remission.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 16, 2024
Case Report: Successful treatment of metastatic retinoblastoma with CNS involvement with anti-GD2 immunotherapy, intrathecal topotecan and reduced systemic chemotherapy.
Journal: Frontiers in pediatrics
Published: October 11, 2024
Naxitamab-combination Therapy for the Treatment of Patients With Refractory and/or Relapsed High-risk Neuroblastoma.
Journal: Journal of pediatric hematology/oncology
Published: September 23, 2024
Last Updated: 10/31/2025